排名前五的靶点	数量

AGT(血管紧张素原)	2
17β-HSD13(17β-羟基类固醇脱氢酶13)	2
APOC3(载脂蛋白C-Ⅲ)	2
PCSK9(前蛋白转化酶枯草杆菌蛋白酶Kexin-9)	1
ANGPTL3(血管生成素样蛋白-3)	1

关联

项与苏州瑞博生物技术股份有限公司相关的药物

Cosdosiran

靶点

caspase 2

作用机制

caspase 2抑制剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

SR-059

靶点

F11

作用机制

F11抑制剂

在研机构

苏州瑞博生物技术股份有限公司 [+1]

原研机构

苏州瑞博生物技术股份有限公司

在研适应症

稳定型心绞痛 [+5]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

RBD-1016

靶点

HBV-X

作用机制

HBV-X抑制剂

在研机构

苏州瑞博生物技术股份有限公司 [+1]

原研机构

苏州瑞博生物技术股份有限公司

在研适应症

慢性丁型肝炎 [+3]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

项与苏州瑞博生物技术股份有限公司相关的临床试验

NCT07042594

/ Not yet recruiting临床1期

A Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

开始日期2025-08-01

申办/合作机构

苏州瑞博生物技术股份有限公司

NCT06797401

/ Recruiting临床2期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are:
Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia.
Participants will:
Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.

开始日期2025-01-28

申办/合作机构

Ribocure Pharmaceuticals AB

CTIS2023-510369-92-00

/ Recruiting临床2期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia - RC02T001

开始日期2025-01-28

申办/合作机构

Ribocure Pharmaceuticals AB

100 项与苏州瑞博生物技术股份有限公司相关的临床结果

登录后查看更多信息

0 项与苏州瑞博生物技术股份有限公司相关的专利（医药）

登录后查看更多信息

项与苏州瑞博生物技术股份有限公司相关的文献（医药）

2025-09-01·Molecular Therapy-Nucleic Acids

A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection

Article

作者: Gao, Shan ; Zheng, Shuquan ; Gan, Li-Ming ; Sun, Qi ; Guo, Chun ; Yan, Xu ; Liang, Zicai ; Zhang, Min ; Zhang, Hongyan ; Cao, Huiqing

Potent small interfering RNA (siRNA) drugs that could achieve hepatitis B surface antigen (HBsAg) seroconversion and functional cure are currently lacking. The purpose of this study is to evaluate the therapeutic potential of RBD1016, a novel GalNAc-conjugated siRNA drug targeting transcripts of hepatitis B virus (HBV), in animal models. RBD1016 was designed to target X gene of HBV (HBx) and showed strong activities on HBV DNA and HBsAg for multiple HBV genotypes and nucleoside-resistant viral strains in in vitro studies. Through single and repeated administration of RBD1016 in two different HBV animal models, a robust reduction of both serum HBsAg and HBV DNA (maximum reduction 3.7 log) was demonstrated. The durable anti-HBV effects of RBD1016 could still be observed on day 169. Importantly, repeated or single administration of RBD1016 caused de novo production of hepatitis B surface antibody (HBsAb), i.e., seroconversion in animals, which is an important hallmark of immune response induction. Furthermore, the combination of RBD1016 and entecavir (ETV) demonstrated an enhanced effect on serum HBV DNA inhibition. A strong and durable anti-HBV effect of RBD1016, both alone and in combination with nucleoside analogues (NAs), indicates significant therapeutic potential for chronic hepatitis B (CHB) patients.

2025-09-01·AMERICAN JOURNAL OF CARDIOLOGY

A Phase 1b Randomized Clinical Trial of AZD5642 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment

Article

作者: Connolly, Kathleen ; Greasley, Peter ; Chan, Melanie ; Svedlund, Sara ; Quintana-Hayashi, Macarena Paz ; Sadaat, Masood ; Rosenmeier, Jaya Birgitte

AZD5462 is the first oral selective relaxin/insulin-like family peptide receptor 1 agonist in clinical development. The aim of this mechanistic study is to investigate the renal effects of AZD5462 when administered on top of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with heart failure and moderate renal impairment. AURORA is a phase 1b, placebo-controlled, double-blind, 2-centre study of AZD5462 on top of dapagliflozin as standard of care in 2 arms. Approximately 40 participants with heart failure with ejection fraction ≤50% and moderate renal impairment (estimated glomerular filtration rate of 30-60 mL/min/1.73 m², inclusive) will be randomized 1:1 to AZD5462 or placebo tablets for a treatment period of 4 weeks. All participants will be standardized to 10 mg dapagliflozin prior to AZD5462 administration, and dapagliflozin as standard of care will continue until the end of the follow-up period. The objectives of the study are to evaluate the renal and haemodynamic effects of AZD5462 compared with placebo on top of dapagliflozin on natriuresis, albuminuria, haematocrit, fluid balance, cardiorenal biomarkers, and systemic hemodynamics. The safety and tolerability of AZD5462 will be further evaluated compared with placebo on top of dapagliflozin. AURORA is a phase 1b pharmacodynamic, pharmacokinetic, and safety study of AZD5462 on top of dapagliflozin in patients with heart failure and renal impairment.

2025-06-02·ORAL DISEASES

Chinese Expert Consensus on Management of Betel-Chewing-Related Oral Squamous Cell Carcinoma.

Review

作者: Liu, Binjie ; Tang, Zhangui ; Peng, Xin ; Xu, Pu ; Ren, Guoxin ; Meng, Jian ; Xing, Lu ; Bu, Rongfa ; Li, Longjiang ; Guo, Wei ; Sun, Moyi ; Gao, Shan ; Hu, Yanjia ; Shang, Wei ; Bin, Xin ; Li, Bo

OBJECTIVE:

Betel-chewing-related oral squamous cell carcinoma (BCR-OSCC) has become a global health issue with increasing incidence year by year around the world. Active prevention of the occurrence of BCR-OSCC, monitoring the population exposed to Betel Nuts, and early diagnosis and treatment are very important to maintain and improve the quality of life of patients. However, there is currently no consensus or guideline that provides targeted guidance on the management of BCR-OSCC.

SUBJECTS AND METHODS:

A consensus panel consisting of 15 leading Chinese experts from multidisciplinary fields was convened, and a roundtable meeting was held to discuss the topics of BCR-OSCC.

RESULTS:

Based on existing research reports and the experts' clinical experiences, a consensus on staging, diagnosis, and treatment for BCR-OSCC was formed through extensive discussion.

CONCLUSION:

This manuscript presents consensus recommendations and a summary of evidence supporting each recommendation. This consensus may improve clinical practices about BCR-OSCC in China and propel more clinical trials to provide high-level evidence for BCR-OSCC management.

725

项与苏州瑞博生物技术股份有限公司相关的新闻（医药）

2025-09-15

·同写意

慢性乙肝适应症获批IND，来恩生物TCR-T疗法三获FDA认可！

细胞疗法信使RNA临床申请临床1期孤儿药

2025-09-11

·同写意

康希诺生物：创新不止，世界无疫 | 写意会员

疫苗优先审批信使RNA临床2期

2025-09-10

·同写意

瑞吉生物肿瘤产品管线取得新进展丨会员动态

细胞疗法疫苗信使RNA

100 项与苏州瑞博生物技术股份有限公司相关的药物交易

登录后查看更多信息

100 项与苏州瑞博生物技术股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年09月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Cosdosiran ( caspase 2 )	缺血性视神经病变更多	临床3期
RBD-1016 ( HBV-X )	乙型肝炎更多	临床2期
SR-059 ( F11 )	血栓栓塞更多	临床2期
RBD-5044 ( APOC3 )	高脂血症更多	临床2期
RBD-7022 ( PCSK9 )	原发性高胆固醇血症更多	临床2期